Depakote and Trileptal Should NOT Be Used for Agitation in Elderly Dementia Patients
Neither Depakote (valproic acid) nor Trileptal (oxcarbazepine) are appropriate for treating agitation in elderly patients with dementia, and both should be avoided in this population.
Evidence Against Depakote (Valproic Acid)
The evidence consistently demonstrates that valproate is ineffective and potentially harmful in this population:
Efficacy: A Cochrane systematic review found moderate-quality evidence that valproate has probably little or no effect on agitation over 6 weeks, measured by both the Brief Psychiatric Rating Scale (BPRS) and Cohen-Mansfield Agitation Index (CMAI) 1.
Adverse Effects: Valproate-treated patients experienced significantly more adverse events (OR 2.02,95% CI 1.30-3.14) and possibly more serious adverse events (OR 4.77,95% CI 1.00-22.74) 1. Common problems included sedation, gastrointestinal symptoms, and urinary tract infections.
FDA Warning: The FDA label specifically warns about somnolence in the elderly with dementia, noting significantly higher rates of somnolence, dehydration, reduced nutritional intake, and weight loss compared to placebo 2. Discontinuations for somnolence were significantly higher than placebo.
Functional Decline: Valproate treatment was associated with slightly worse functional ability (MD 1.19,95% CI 0.40-1.98 on the Physical Self-Maintenance Scale) 1.
Evidence Against Trileptal (Oxcarbazepine)
The data for oxcarbazepine is limited but consistently negative:
No Efficacy: An 8-week randomized controlled trial of 103 institutionalized dementia patients found no statistically significant differences between oxcarbazepine and placebo for agitation/aggression on the Neuropsychiatric Inventory or caregiver burden 3.
Limited Evidence Base: A 2024 systematic review concluded there is low-quality evidence that oxcarbazepine is likely ineffective for behavioral and psychological symptoms of dementia 4.
What the Guidelines Actually Recommend
The 2016 APA guidelines focus exclusively on antipsychotics (not anticonvulsants) for severe agitation in dementia, and only under specific conditions 5:
- Antipsychotics should only be used when symptoms are severe, dangerous, and/or cause significant distress
- Nonpharmacological interventions must be tried first
- Treatment requires informed discussion of risks/benefits with patient and surrogate decision-makers
- Start at low doses and taper if no response after 4 weeks
The guidelines make no mention of anticonvulsants like Depakote or Trileptal as treatment options, which is telling given their comprehensive scope.
Clinical Bottom Line
Avoid both medications for dementia-related agitation. If pharmacological intervention is absolutely necessary after exhausting nonpharmacological approaches:
- Consider antipsychotics (brexpiprazole, risperidone, or aripiprazole) with careful risk-benefit discussion 6
- Selected antidepressants (citalopram, agomelatine) may be safer alternatives when tolerability is the priority 6
- Recent evidence suggests quetiapine had lower adverse event rates (OR 0.27,95% CI 0.08-0.97) compared to haloperidol in older adults with severe agitation 7
Key Pitfalls to Avoid
- Do not use valproate based on outdated practices or anecdotal experience—the evidence clearly shows harm without benefit
- Monitor closely if a patient is already on these medications; consider tapering and discontinuation
- Recognize the FDA warning: elderly dementia patients on valproate require monitoring for somnolence, dehydration, and nutritional intake 2
- Be aware that one recent retrospective study from China suggested possible benefit 8, but this contradicts higher-quality prospective evidence and should not change practice